-
until 2024 as the
European Monitoring Centre for
Drugs and Drug
Addiction (
EMCDDA), is an
agency of the
European Union headquartered in Lisbon, Portugal,...
-
reported to the
European Monitoring-Center for
Drugs and Drug
Addiction (
EMCDDA).
Reported user
negative effects include palpitations, paranoia, intense...
-
According to the
European Monitoring Centre for
Drugs and Drug
Addiction (
EMCDDA) it has been
detected in 25
European countries with the
majority of drug...
-
found being sold as a
designer drug in the UK in 2010, and
reported to the
EMCDDA new drug
monitoring service. It was
described by
Alexander Shulgin as similar...
- web}}: CS1 maint:
archived copy as
title (link) "
EMCDDA:Drug
policy profiles, Portugal, June 2011".
Emcdda.europa.eu. 17
August 2011.
Retrieved 27 July 2014...
- Drug profiles.
European Monitoring Centre for
Drugs and Drug
Addiction (
EMCDDA). 8
January 2015.
Archived from the
original on 15
April 2016. Retrieved...
- ADB-BUTINACA (also
known as ADMB-BINACA
using EMCDDA naming standards) is a
synthetic cannabinoid compound which has been sold as a
designer drug. It is...
- doi:10.1021/ja00212a065. "Barbiturates drug
profile | www.
emcdda.europa.eu". www.
emcdda.europa.eu.
Retrieved 22
December 2021. "Wolf D. Kuhlmann, "Buffer...
- α-PiHP was
first identified as a
designer drug when it was
reported to the
EMCDDA by a
forensic laboratory in Slovenia. It is a
positional isomer of pyrovalerone...
- €3 to €9 per tablet,
typically containing 25–65 mg of MDMA. By 2014 the
EMCDDA reported that the
range was more
usually between €5 and €10 per tablet,...
